Nexalin Technology, Inc. announced on April 14, 2025, that the United States Patent and Trademark Office (USPTO) officially granted its patent titled "Alternating Current Dynamic Frequency Stimulation Method for Opioid Use Disorder (OUD) and Substance Use Disorder (SUD)." This milestone strengthens Nexalin’s intellectual property portfolio.
The newly granted patent covers Nexalin’s proprietary Deep Intracranial Frequency Stimulation (DIFS™) technology, a non-invasive and drug-free solution. It is designed to aid individuals struggling with various substance use disorders, including opioid use disorder, alcohol use disorder, and stimulant addiction.
By applying non-invasive deep-brain stimulation at dynamic frequencies, DIFS™ technology may help regulate neural pathways linked to addiction and withdrawal symptoms. This offers an alternative treatment pathway for individuals seeking recovery, potentially alleviating anxiety, depression, and cravings that often lead to relapse.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.